Diabetes (type 2) - empagliflozin [ID641]

Anticipated publication date:

Empagliflozin for treating type 2 diabetes
 
Status
In development
Anticipated publication date
March 2015
Process
STA
Referral date
October 2013
Topic area
  • Endocrine, nutritional and metabolic

Provisional Schedule

Closing date for invited submissions / evidence submission: 23 April 2014
1st appraisal committee meeting: 29 July 2014
2nd appraisal committee meeting 25 November 2014

Project Team

Executive Lead: TBC
Technical Lead: Anwar Jilani
Communications manager: Elizabeth Adelanwa
Project manager:

Bijal Joshi

Timeline

Key events during the development of the guidance

Date
Update
10 September 2014

In the Appraisal Consultation Document (ACD) for the appraise of empagliflozin combination therapy for treating type 2 diabetes [ID641], the Appraisal Committee requested further analyses from the company.

Boehringer Ingelheim has indicated that new economic analyses will be submitted in response to this request. In order to allow a complete set of analyses as requested by the Committee to be produced, and for those analyses to be reviewed by the Evidence Review group, NICE has agreed an extension in timings. Therefore the second Committee Meeting has been rescheduled to 25 November 2014.

Get involved